About

Susan E. Graf has served on Aardvark's Board since November 2024. Since May 2021 she has been a Senior Advisor and Entrepreneur in Residence at Locust Walk Partners, LLC. She was Chief Executive Officer of Akamara Therapeutics from 2019 to 2021 and Chief Business Officer (and Principal Financial Officer) of Epizyme, Inc. from 2016 to 2018, and earlier held roles at NPS Pharma and spent nearly 18 years at Roche. Ms. Graf received her M.B.A. from the Stern School of Business at New York University and her B.Pharm. from Purdue University. She serves on Aardvark's Compensation and Audit Committees.

Roles

Aardvark Therapeutics, Inc.
Director · Current role
November 2024–present
Locust Walk Partners, LLC
Senior Advisor & Entrepreneur in Residence
2021 - present
Akamara Therapeutics, Inc.
Chief Executive Officer
2019 - 2021
Epizyme, Inc.
Chief Business Officer (and Principal Financial Officer)
2016 - 2018
NPS Pharma
Vice President, Corporate Development and Strategy
Roche
Various leadership and executive positions · ~18 years

External Roles

CG Oncology, Inc.
Director & Audit Committee Chair
2021 - present
Kaleo, Inc.
Director
present
Finch Therapeutics, Inc.
Chair of the Board & Audit Committee
2021 - 2024

Director Compensation

FY 2025
Fees earned or paid in cash
$61,562
ComponentAnnual cash retainers and committee/leadership fees earned in 2025
Option awards
$277,568
ComponentStock options granted during 2025, ASC 718 grant-date fair value
Total
$339,130

Also at Aardvark Therapeutics, Inc.

Related

See how VectorShift works for your firm

Request Demo